Study of a new drug combo for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have never been treated for DLBCL before.
- You have a type of DLBCL confirmed by a biopsy.
- Your cancer shows up brightly on a PET scan (score 4 or 5).
- You are well enough to be up and about (ECOG score 0 to 2).
- Your heart pumps blood effectively (ejection fraction of 45% or higher).
- You do not have serious heart problems, nerve damage, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.